Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
97% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ALNY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALNY' s 10-Year Cash to Debt Range
Min: 3.29  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ALNY's Equity to Asset is ranked higher than
88% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALNY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ALNY' s 10-Year Equity to Asset Range
Min: -0.99  Med: 0.56 Max: 0.92
Current: 0.92
-0.99
0.92
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
95% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 47.12
M-Score: 31.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -309.32
ALNY's Operating margin (%) is ranked lower than
67% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ALNY: -309.32 )
Ranked among companies with meaningful Operating margin (%) only.
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93  Med: -188.54 Max: -28.95
Current: -309.32
-14236.93
-28.95
Net-margin (%) -263.43
ALNY's Net-margin (%) is ranked lower than
66% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ALNY: -263.43 )
Ranked among companies with meaningful Net-margin (%) only.
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3  Med: -163.40 Max: -27.3
Current: -263.43
-14223.3
-27.3
ROE (%) -15.31
ALNY's ROE (%) is ranked higher than
61% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ALNY: -15.31 )
Ranked among companies with meaningful ROE (%) only.
ALNY' s 10-Year ROE (%) Range
Min: -363.95  Med: -42.70 Max: -13.08
Current: -15.31
-363.95
-13.08
ROA (%) -13.79
ALNY's ROA (%) is ranked higher than
60% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ALNY: -13.79 )
Ranked among companies with meaningful ROA (%) only.
ALNY' s 10-Year ROA (%) Range
Min: -97.61  Med: -24.25 Max: -5.01
Current: -13.79
-97.61
-5.01
ROC (Joel Greenblatt) (%) -996.54
ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ALNY: -996.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2120.98  Med: -391.31 Max: -149.42
Current: -996.54
-2120.98
-149.42
Revenue Growth (3Y)(%) -29.60
ALNY's Revenue Growth (3Y)(%) is ranked lower than
75% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALNY: -29.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 7.90 Max: 108
Current: -29.6
0
108
EBITDA Growth (3Y)(%) 65.40
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ALNY: 65.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.8  Med: -6.10 Max: 65.4
Current: 65.4
-64.8
65.4
EPS Growth (3Y)(%) 52.80
ALNY's EPS Growth (3Y)(%) is ranked higher than
92% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ALNY: 52.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7  Med: -4.00 Max: 52.8
Current: 52.8
-66.7
52.8
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ALNY Guru Trades in Q3 2014

Steven Cohen 12,100 sh (New)
Vanguard Health Care Fund 5,277,100 sh (+6.10%)
Pioneer Investments 324,287 sh (unchged)
Columbia Wanger 554,000 sh (-29.38%)
» More
Q4 2014

ALNY Guru Trades in Q4 2014

John Griffin 430,000 sh (New)
Paul Tudor Jones 3,540 sh (New)
Bill Frels 2,200 sh (New)
Pioneer Investments 483,213 sh (+49.01%)
Steven Cohen Sold Out
Vanguard Health Care Fund 5,030,100 sh (-4.68%)
Columbia Wanger 477,700 sh (-13.77%)
» More
Q1 2015

ALNY Guru Trades in Q1 2015

Louis Moore Bacon 5,500 sh (New)
Julian Robertson 161,600 sh (New)
John Griffin 960,000 sh (+123.26%)
Vanguard Health Care Fund 6,094,810 sh (+21.17%)
Pioneer Investments 484,824 sh (+0.33%)
Bill Frels 2,200 sh (unchged)
Paul Tudor Jones Sold Out
Columbia Wanger 402,500 sh (-15.74%)
» More
Q2 2015

ALNY Guru Trades in Q2 2015

Vanguard Health Care Fund 6,094,810 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked higher than
52% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. ALNY: 23.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.05
ALNY's P/B is ranked lower than
66% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ALNY: 7.05 )
Ranked among companies with meaningful P/B only.
ALNY' s 10-Year P/B Range
Min: 2.07  Med: 4.68 Max: 21.38
Current: 7.05
2.07
21.38
P/S 161.12
ALNY's P/S is ranked lower than
89% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ALNY: 161.12 )
Ranked among companies with meaningful P/S only.
ALNY' s 10-Year P/S Range
Min: 3.09  Med: 20.80 Max: 189.72
Current: 161.12
3.09
189.72
EV-to-EBIT -50.52
ALNY's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ALNY: -50.52 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s 10-Year EV-to-EBIT Range
Min: -58.7  Med: -9.00 Max: -1.3
Current: -50.52
-58.7
-1.3
Current Ratio 13.51
ALNY's Current Ratio is ranked higher than
84% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALNY: 13.51 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s 10-Year Current Ratio Range
Min: 1.88  Med: 4.46 Max: 13.51
Current: 13.51
1.88
13.51
Quick Ratio 13.51
ALNY's Quick Ratio is ranked higher than
84% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ALNY: 13.51 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s 10-Year Quick Ratio Range
Min: 1.88  Med: 4.46 Max: 13.51
Current: 13.51
1.88
13.51
Days Sales Outstanding 60.65
ALNY's Days Sales Outstanding is ranked lower than
51% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. ALNY: 60.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s 10-Year Days Sales Outstanding Range
Min: 0.57  Med: 36.08 Max: 288.31
Current: 60.65
0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.34
ALNY's Price/Net Cash is ranked lower than
62% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ALNY: 11.34 )
Ranked among companies with meaningful Price/Net Cash only.
ALNY' s 10-Year Price/Net Cash Range
Min: 3.7  Med: 9.40 Max: 92.77
Current: 11.34
3.7
92.77
Price/Net Current Asset Value 11.06
ALNY's Price/Net Current Asset Value is ranked lower than
62% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ALNY: 11.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.54  Med: 9.18 Max: 82.06
Current: 11.06
3.54
82.06
Price/Tangible Book 7.08
ALNY's Price/Tangible Book is ranked lower than
57% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ALNY: 7.08 )
Ranked among companies with meaningful Price/Tangible Book only.
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.2  Med: 4.87 Max: 15.17
Current: 7.08
2.2
15.17
Price/Projected FCF 85.63
ALNY's Price/Projected FCF is ranked lower than
92% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. ALNY: 85.63 )
Ranked among companies with meaningful Price/Projected FCF only.
ALNY' s 10-Year Price/Projected FCF Range
Min: 1.86  Med: 2.58 Max: 83.21
Current: 85.63
1.86
83.21
Price/Median PS Value 7.76
ALNY's Price/Median PS Value is ranked lower than
95% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ALNY: 7.76 )
Ranked among companies with meaningful Price/Median PS Value only.
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.16  Med: 0.98 Max: 7.09
Current: 7.76
0.16
7.09
Earnings Yield (Greenblatt) (%) -1.97
ALNY's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ALNY: -1.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALNY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6  Med: 465.90 Max: 1781.6
Current: -1.97
-6
1781.6

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 73 76 63
EPS($) -2.75 -3.03 -2.72
EPS without NRI($) -2.75 -3.03 -2.72

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" — the molecules that mediate RNAi — toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
comment on ALNY Mar 09 2013 
comment on ALNY Mar 02 2013 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 06 2009 
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results Feb 17 2009 

More From Other Websites
Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results Jul 30 2015
Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results Jul 30 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-HBV for the treatment of Hepatitis B Virus... Jul 28 2015
Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the... Jul 27 2015
Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the... Jul 27 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment of Hemophilia and Rare... Jul 22 2015
Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") with Patisiran, an... Jul 20 2015
Alnylam Initiates Phase 3 Open Label Extension Study (“APOLLO-OLE”) with Patisiran, an... Jul 20 2015
Faruqi & Faruqi, LLP is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) on Behalf of its... Jul 17 2015
Alnylam to Reschedule First RNAi Roundtable Webcast Jul 16 2015
Alnylam to Reschedule First RNAi Roundtable Webcast Jul 16 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Jul 14 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 10 2015
Alnylam to Host Second Annual Summer "RNAi Roundtable" Webcast Series Jul 06 2015
Alnylam to Host Second Annual Summer “RNAi Roundtable” Webcast Series Jul 06 2015
Alnylam Reports Encouraging New Data on Hemophilia Drug - Analyst Blog Jun 24 2015
What's The Street Think Of Alnylam Pharmaceuticals New Drug Data? Jun 24 2015
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015
Alnylam Pharmaceuticals Inc to Discuss ALN-AT3 Phase 1 Clinical Data Call scheduled for 4:30 pm ET... Jun 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK